PerkinElmer Inc, Formerly RHS Ltd

In June 2018, RHS Limited (ASX:RHS) was acquired by PerkinElmer Inc. The PG-Seq range of kits are at the forefront of single cell genomic analysis. Genetics is changing the world of medicine and accelerating biomedical research. The ability to cost effectively sequence the entire human genome has already led to significant medical and scientific breakthroughs. We play an important role in the critical first steps within this genetics revolution. For instruments to be able to sequence DNA, they often needs thousands, if not millions of cells worth of DNA. However, often there is very little DNA to work with. The DOPlify™ kit is a core technology platform that is optimised to take DNA from a single cell and amplify it, resulting in a sample that can then be sequenced and analysed. The PG-Seq range is a complete workflow for detecting copy number changes from single cells and small numbers of cells. PG-Seq kit 2.0 starts with the DOPlify whole genome amplification followed by NGS library preparation. PG-Seq Rapid kits are a platform agnostic two step PCR-based sample preparation solution. The PG-Seq Rapid Non-invasive kit has been developed and optimized specifically for preparing cell-free DNA from spent culture media. For more information about PerkinElmer and our single cell genomics products, please visit the website at https://perkinelmer-appliedgenomics.com/home/products/preimplantation-genetic-testing/